Famciclovir for Treatment of Herpesvirus Infections

@article{Luber1996FamciclovirFT,
  title={Famciclovir for Treatment of Herpesvirus Infections},
  author={Andrew D. Luber and John F. Flaherty},
  journal={Annals of Pharmacotherapy},
  year={1996},
  volume={30},
  pages={978 - 985}
}
OBJECTIVE: To discuss the antiviral activity, pharmacokinetics, clinical efficacy, and adverse effect profile of famciclovir, the oral prodrug of penciclovir (PCV), and to compare these features of famciclovir with those of acyclovir in the treatment of herpesvirus infections. DATA SOURCES: Literature was identified by MEDLINE search, and abstracts from recent meetings were included where relevant. Data provided by the manufacturer were also used. STUDY SELECTION: Data regarding antiviral… Expand
Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster
TLDR
Oral acyClovir, valacyclovir and famciclovir are efficacious and safe for the treatment of the first episode and recurrent genital herpes and are useful as suppressive therapy for individuals with frequent genital herpes recurrences. Expand
Valacyclovir in the treatment of genital herpes and herpes zoster
  • D. Baker
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2002
TLDR
Valacyclovir is well tolerated, with convenient dosing frequencies for the treatment of genital herpes or herpes zoster, it also has the option for use as a short course therapy in the episodic treatment of recurrent genital herpes, all of which are important benefits in the management of these conditions. Expand
Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and Other Viral Infections
TLDR
Valacyclovir is safe and effective in the therapy of patients with herpes simplex and herpes zoster and may be useful in other viral infections. Expand
Valacyclovir for the treatment of genital herpes
TLDR
Valacyclovir has an acceptable safety profile in patients with herpes simplex and herpes zoster, and the less frequent dosing regimen makes it an attractive option in the treatment of genital herpes and other viral infections, and may contribute to increased patient adherence to therapy. Expand
Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and other Viral Infections
Background: Genital herpes and herpes labialis are prevalent, physically and pychologically painful, and often disabling. Herpes zoster is often very painful and may result in months or years ofExpand
Chapter 12 Clinical Trials in Central Nervous System Infections
TLDR
Clinical trials in HIV-1 infection of the CNS have focused both on primary HIV associated disorders, such as dementia, and opportunistic infections, including toxoplasmosis, cryptococcal meningitis, cytomegalovirus encephalitis, progressive multifocal leukoencephalopathy, and primary CNS lymphoma. Expand
Distribution to the skin of penciclovir after oral famciclovir administration in healthy volunteers: comparison of the suction blister technique and cutaneous microdialysis.
TLDR
Both the suction blister technique and microdialysis showed that penciclovir reaches the skin in concentrations sufficient to inhibit herpes virus replication. Expand
Clinical management of selected oral fungal and viral infections during HIV-disease.
TLDR
Current possibilities of management of selected fungal and viral oral opportunistic infections including oral candidiasis, herpes simplex type 1 and 2-related lesions, oral hairy leukoplakia, and oral lesions associated with human papilloma viruses are described. Expand
Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
TLDR
Nucleoside antimetabolites—approved antineoplastic agents—that have recently been shown to have antiviral and/or antibacterial activity are presented. Expand
Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection
TLDR
Currently available anti-herpetic therapies, novel molecules being assessed in clinical trials and new botanical compounds reported in the last 20 years with antiviral activities against HSVs that might represent future treatments against these viruses are reviewed. Expand
...
1
2
...

References

SHOWING 1-10 OF 42 REFERENCES
Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients.
  • H. Degreef
  • Medicine
  • International journal of antimicrobial agents
  • 1994
TLDR
Famciclovir, administered less frequently and at lower unit doses than acyclovir, is an effective treatment for patients with uncomplicated herpes zoster and was well tolerated with a safety profile comparable to that of acy Clovir. Expand
Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.
TLDR
Oral aciclovir has prevented recurrence of HSV genital or orofacial infections during suppressive therapy in > 70% of immunocompetent patients in most clinical trials and appears to offer partial protection from invasive CMV disease in CMV-seropositive bone marrow transplant recipients. Expand
Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern
The antiherpesvirus agent penciclovir has been evaluated extensively in cell culture. The spectrum of activity of penciclovir against human herpesviruses is similar to that of acyclovir, bothExpand
Safety of famciclovir in patients with herpes zoster and genital herpes
TLDR
Safety data from the analysis of 13 completed clinical studies demonstrate that famciclovir is tolerated well by patients with either herpes zoster or genital and has a safety profile comparable to that of placebo. Expand
Famciclovir and Penciclovir. The Mode of Action of Famciclovir Including Its Conversion to Penciclovir
TLDR
The efficient entrapment of the active moiety can account for the markedly better antiviral activity of penciclovir than acyclovir when infected cell cultures were treated for a short time. Expand
Efficacy of oral acyclovir treatment of acute herpes zoster.
TLDR
No significant hastening of rash healing was seen in those who started therapy later than 48 hours after the onset of rash, and acyclovir produced no effects on the frequency or severity of post-herpetic neuralgia. Expand
Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes.
TLDR
It is shown that BRL 42359 is oxidized to penciclovir in cytosol but not in microsomes and that this reaction was not dependent on the presence of NADPH, and it seems that this oxidation is not catalyzed by cytochrome P-450. Expand
Pharmacokinetics of Famciclovir in Single and Repeat Administration in Humans
TLDR
There was no evidence for drug accumulation and for alternation of the pharmacokinetics of famciclovir by the repeat dose regimen studied, and the urinary excretions and total metabolites determined were statistically not different between Days 1 and 7, and also between Day 1 and through the administration period. Expand
Pharmacokinetics of Famciclovir in Subjects with Chronic Hepatic Disease
TLDR
The data suggest a decrease in the rate, but not the extent, of systemic availability of penciclovir in patients with hepatic disease, and it should be unnecessary to modify the dose of famcic Lovir for subjects with compensated liver disease and normal renal function. Expand
Pharmacokinetics of acyclovir after intravenous and oral administration.
TLDR
Acyclovir half-life (T1/2 beta) and total body clearance (Cltot) are influenced significantly by renal function, and dosage adjustments should be made for patients with impaired renal function; therefore dosage adjustments based on Clcr will compensate for age-related changes in renal function. Expand
...
1
2
3
4
5
...